VeriStrat is a test developed to evaluate patient prognosis and, additionally, predict benefit from cancer treatment by
EGFR inhibitor
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.
The epidermal growth factor rece ...
s. It is a serum/plasma
proteomic
Proteomics is the large-scale study of proteins. Proteins are vital parts of living organisms, with many functions such as the formation of structural fibers of muscle tissue, enzymatic digestion of food, or synthesis and replication of DNA. In ...
test developed using matrix-assisted laser desorption/ionization (
MALDI
In mass spectrometry, matrix-assisted laser desorption/ionization (MALDI) is an ionization technique that uses a laser energy absorbing matrix to create ions from large molecules with minimal fragmentation. It has been applied to the analysis of ...
)
mass spectrometry
Mass spectrometry (MS) is an analytical technique that is used to measure the mass-to-charge ratio of ions. The results are presented as a ''mass spectrum'', a plot of intensity as a function of the mass-to-charge ratio. Mass spectrometry is use ...
.
VeriStrat was developed by Biodesix, Inc., a molecular diagnostics company based in Boulder, Colorado, US.
The VeriStrat
algorithm
In mathematics and computer science, an algorithm () is a finite sequence of rigorous instructions, typically used to solve a class of specific Computational problem, problems or to perform a computation. Algorithms are used as specificat ...
has been interrogated retrospectively and prospectively in samples from randomized trials, such as the PROSE study, confirming the prognostic information associated with the
molecular signature. In addition, the test appeared to be predictive of
erlotinib
Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) â ...
impact on survival, as only "VeriStrat Good patients" benefited from such a treatment. Additional studies have confirmed its clinical relevance.
References
* Original article describing the test: http://jnci.oxfordjournals.org/content/99/11/838.full.pdf+html
*Lung Cancer Journal, “Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial”, Hornberger et al.
*"Predictive value of a proteomic signature in patients with non-small cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker stratified, randomised phase 3 trial," Gregorc et al. The Lancet Oncology
*A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non-Small-Cell Lung Cancer. Stinchcombe, et al. Journal of Thoracic Oncology.
Medical tests
Targeted therapy
{{oncology-stub